KURA ONCOLOGY

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER

November 20, 2024

Forward-Looking Statements

This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, KO-2806 and tipifarnib, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive therapies, our expectations regarding the therapeutic and commercial potential of our product candidates, and our expectations regarding our collaboration with Kyowa Kirin. The words "believe," "may," "should," "will," "estimate," "promise," "plan", "continue," "anticipate," "intend," "expect," "potential" and similar expressions (including the negative thereof) are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: our preclinical studies and clinical trials may not be successful; the U.S. Food and Drug Administration (FDA) may not agree with our interpretation of the data from clinical trials of our product candidates; we may decide, or the FDA may require us, to conduct additional clinical trials or to modify our ongoing clinical trials; we may experience delays in the commencement, enrollment, completion or analysis of clinical testing for our product candidates, or in the reporting of data from such clinical testing, or significant issues regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise, which could result in increased costs and delays, or limit our ability to obtain regulatory approval; our product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of our product candidates could delay or prevent regulatory approval or commercialization; we may not be able to obtain additional financing; and our collaboration with Kyowa Kirin may not be successful. Additional risks and uncertainties may emerge from time to time, and it is not possible for Kura's management to predict all risk factors and uncertainties.

All forward-looking statements contained in this presentation speak only as of the date on which they were made. Other risks and uncertainties affecting us are described more fully in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This presentation also contains statistical and clinical data obtained from and prepared by third parties. The recipient is cautioned not to give undue weight to such disclosures. Neither the Company nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation.

Kura Oncology Investment Thesis

- Robust pipeline of potential blockbuster product opportunities in hematologic malignancies, solid tumors and diabetes
- Kyowa Kirin strategic collaboration accelerates expansive global development and commercialization to maximize the potential of ziftomenib for AML patients
- Kura retains program leadership in the U.S. and key strategic rights of ziftomenib to preserve strategic flexibility
- Kura retains pipeline programs, which are funded through key value inflection points in 2025-2026, including:
    - Next-gen menin inhibitors targeting oncology, diabetes and other metabolic diseases
    - Farnesyl transferase inhibitor combinations
- Kura anticipates collaboration plus current cash balance to fund AML program to commercialization in frontline combinations

Strategic Collaboration with Kyowa Kirin Positions Kura to Unlock the Value of Ziftomenib and Pipeline

- Well-aligned partner with development, operational and commercial expertise and long-term vision to capitalize on the full promise of ziftomenib in AML
- Enables broad development and commercialization, including 1L fit and unfit, combinations with targeted therapies and post-transplant maintenance setting
- Kura retains leadership and key strategic rights of ziftomenib in the U.S. to preserve strategic flexibility while accelerating its path toward becoming a fully-integrated commercial biopharmaceutical company
- Kura maintains rights to its programs while accelerating associated opportunities
- Along with current cash balance, fully funds ziftomenib AML program through to commercialization of frontline combinations – multi-$B opportunities

Summary of Collaboration Terms

Scope	Broad development & commercialization of ziftomenib in acute leukemias, including frontline indications, post-transplant maintenance setting and combinations with targeted therapies
Upfront Payment	Kura will receive $330M upon closing
Near-Term Milestones	$420M, including milestones upon NDA filing and first commercial sale in the monotherapy R/R setting
Total Milestones	$1.2B in total development, regulatory and commercial milestone payments
Development	• Kura leads global development and U.S. regulatory* • Kyowa Kirin leads regulatory ex-U.S.
Commercial Rights	• 50/50 US co-commercialization and profit/loss share • Kura books U.S. revenue • Kyowa Kirin leads regulatory and commercialization outside U.S.
Opt-in Right for Solid Tumors	Kyowa Kirin to have ability to opt-in to development and commercialization of ziftomenib in gastrointestinal stromal tumors (GIST) and other solid tumors; triggers up to $228M in additional upfront and milestone payments
Ex-U.S. Royalties	Tiered double-digit royalties

* Kura funds the development costs until the end of 2028, and from 2029 onwards, both companies will share the costs at a 50:50 ratio

Company Overview

Abdul Mullick, Ph.D.
Managing Executive Officer
and Chief International Business Officer

Yasuo Fujii, MBA
Managing Executive Officer
and Chief Strategy Officer

Kyowa Kirin is a growing global specialty pharmaceutical company with a strong commercial track record

- Kyowa Kirin strives to create and deliver novel medicines with life-changing value.
- As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, we apply cutting-edge science, including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas.

50 Markets

Extensive market reach, with a presence worldwide in 2023

65%

Overseas revenue ratio in 2023

120%

Sales growth for the three global strategic products (vs. 2022)

5,974

Valuable employees worldwide

$3.1 billion

Annual consolidated revenue in 2023

Company Overview

As of Dec31,2023

Kyowa Kirin has a long history of providing life-changing value in the treatment of HemOnc diseases

60's 70's 80's 90's 00's 10's

1963
Mitomycin
CLL, CML, Solid tumors

1971
Leunase
Pediatric ALL

1975-2017
Adriamycin
Lymphoma, Solid tumors

1980
5-FU
Solid tumors

1982
Nauzelin
Gastritis



1987
Hysron
BRC, Endometrial Ca.

1986-2017
Dacarbazine
Hodgkin lymphoma, Melanoma

1990
ESPO
Renal anemia

1991
GRAN
Neutropenia, Mobilization of HPC

1999
Navelbine
NSCLC, BRC

1991-2019
Leukoprol
Neutropenia

1997-2014
Navoban
CI-Gastritis

2007
NESP
Renal anemia, MDS

2006-2013
Busulfex
HSCT conditioning

2010
Fentos
Cancer pain, Chronic Pain

2013
Poteligeo
ATL, PTCL, CTCL

2015
Acoalan
CAD, DIC

2011
Romiplate
ITP, Aplastic anemia

2014
G-LASTA
CIFN, PBSC mobilization

2018
Rituximab BS
Lymphoma, GPA, MPA, ITP, TTP

HemOnc Expertise

*Hematologic indication in red

Story for Vision 2030

Strategies for creating and delivering life-changing value

Disease Science

Focus disease areas: bone & mineral, intractable hematological diseases/hemato oncology, and rare diseases

- Explore UMN, causes and mechanisms of disease in depth
- Pursuit of molecular and cellular regulatory mechanisms for therapeutic realization

Drug Discovery Technology

Strengthening Innovative Modalities: Advanced Antibody Technologies, Hematopoietic stem cell gene therapy

- Application of optimal modalities for therapeutic realization
- Evolution of drug discovery methods through AI and data science

External Collaboration

- Open Innovation
- Partnering

Life-changing Value Creation

Assets in focus disease areas

Strategic Partnering Assets *

Value delivery on our own	Global deployment of products developed by taking full advantage of the company's strengths
Collaborative value delivery	Aim to maximize value by combining the strengths of the company and its partners
Full-licensing	Maximize the value of developed products and deliver them to patients faster by out-licensing to the most appropriate partners

***Assets outside of the disease areas of focus are designated as strategic partnering assets, and value maximization is achieved through collaboration with partners.**

Present and Future Value for Kura Oncology

Collaboration Provides Expansive Development in 50% of Patients for Whom Menin-KMT2A Pathway is a Disease Driver

Prevalence of Ziftomenib Eligible Patients



1L Treatable ~17K → **Relapsed / Refractory** ~14K

1L Treatable			Relapsed / Refractory			
FIT IC* or UNFIT NIC*	Transplant/ No Transplant	Post-Transplant Maintenance	IC or NIC Tx or tolerable therapy	Transplant/ No Transplant	Targeted Tx if FLT3m, IDH1/2m and/or NPM1m	Non-Intensive therapy / Palliative Care

komet ACUTE LEUKEMIAS
Ziftomenib Clinical Trials for Acute Leukemias

KOMET-007
- 1L zifto + ven/aza
- 1L zifto + 7+3
- 1L zifto + 7+3 + quizartinib

KOMET-017
- 1L zifto + ven/aza
- 1L zifto + 7+3

Investigator / Company Sponsored Studies
- Post-HSCT maintenance

KOMET-001
- R/R NPM1m AML

KOMET-007
- R/R zifto + ven/aza

KOMET-008
- R/R zifto + FLAG-IDA
- R/R zifto + LDAC
- R/R zifto + gilteritinib

*FIT IC = patients eligible for induction chemotherapy; UNFIT NIC = patients eligible for non-intensive chemotherapy

Maximize Value of Robust Therapeutic Pipeline

PROGRAM	CLINICAL TRIAL	STUDY STARTUP	DOSE-ESCALATION	DOSE-VALIDATION	REGISTRATION DIRECTED	ANTICIPATED MILESTONE
ZIFTOMENIB Menin Inhibitor	**KOMET-001** Monotherapy	NPM1-mutant acute myeloid leukemia (AML)				Topline data in early 2025
		KMT2A-rearranged acute lymphoblastic leukemia (ALL)				Now dosing patients
		Non-NPM1-mutant / Non-KMT2A-rearranged AML				Now dosing patients
	KOMET-007 Combinations with venetoclax/azacitidine, cytarabine + daunorubicin (7+3)	NPM1-mutant AML				Phase 1b expansion study now enrolling
		KMT2A-rearranged AML				
	KOMET-008 Combinations with gilteritinib, FLAG-IDA, LDAC	NPM1-mutant AML				Now dosing patients
		KMT2A-rearranged AML				
	KOMET-015 Combination with imatinib	Advanced GIST				Initiate proof-of-concept study in 1H 2025
KO-2806 Next-Generation Farnesyl Transferase Inhibitor (FTI)	**FIT-001** Monotherapy, combinations with cabozantinib and adagrasib	Solid tumors				Now in dose escalation as monotherapy
		Clear cell renal cell carcinoma (ccRCC)				Now dosing patients in combo with cabozantinib
		$KRAS^{G12C}$-mutant non-small cell lung cancer (NSCLC)				Now dosing patients in combo with adagrasib
TIPIFARNIB FTI	**KURRENT-HN** Combination with alpelisib	PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC)				Present preliminary data in 1H 2025

KOMET-017: Ziftomenib Pivotal 1L Combination

Fully-funded study expected to start in mid-2025

- Includes two independently powered Phase 3, randomized, double-blind, placebo-controlled studies
- Populations: Adult 1L AML with KMT2A-r or NPM1-m
  - Non-intensive therapy study
    - Ziftomenib + venetoclax + azacitidine
    - Placebo + venetoclax + azacitidine
  - Intensive therapy study
    - Ziftomenib + daunorubicin + cytarabine (7+3)
    - Placebo + daunorubicin + cytarabine (7+3)
- Approximately 150 sites in 20+ countries

Strategic Collaboration Provides Significant Capabilities to Achieve Strategic Goals and Lessens Equity Financing Needs

- **Develop Ziftomenib to Treat up to 50% of AML Patients**
- **Ensure Launch Readiness for Ziftomenib in 2025**
- **Pursue Multi-$B Post-Transplant Maintenance and Targeted Therapy Opportunities**
- **Aggressively Pursue Multi-$ Billion 1L Fit / Unfit Market Opportunities**
- **Bring Menin (GIST, diabetes) and FTI Programs (RCC, KRAS, PI3Kα) to Meaningful Value Inflection Points**
- **Maintain Very Strong Cash Position and Strategic Optionality**

Forecasted Milestones & Financial Highlights

PROGRAM	MILESTONE	ESTIMATED TIME OF ACHIEVEMENT
ZIFTOMENIB **Menin Inhibitor**	Present updated data from KOMET-007 trial in combination with ven/aza and 7+3	ASH 2024
	Report topline results from KOMET-001 registration-directed trial in NPM1-mutant R/R AML	Early 2025
	Present preliminary data from Phase 1b expansion portion of KOMET-007	2025
	Initiate KOMET-015 study in combination with imatinib in patients with advanced GIST	1H 2025
	Nominate a next generation menin inhibitor development candidate	1H 2025
	Initiate KOMET-017 registration-directed trial in combination with ven/aza and 7+3 in 1L AML	Mid-2025
KO-2806 **Next-Generation Farnesyl Transferase Inhibitor**	Identify maximum tolerated dose as monotherapy	2H 2024
	Initiate one or more expansion cohorts in combination with cabozantinib in ccRCC	1H 2025
TIPIFARNIB **Farnesyl Transferase Inhibitor**	Identify OBAD in combination with alpelisib in PIK3CA-dependent HNSCC	End of 2024
	Present data from KURRENT-HN trial in combination with alpelisib in PIK3CA-dependent HNSCC	1H 2025

Financial Highlights Nasdaq: KURA	
	$785.3M in *pro forma* cash as of September 30, 2024*
	Shares outstanding as of September 30, 2024: 77.7M basic; 24.5M options, RSUs, PSUs, warrants & pre-funded warrants

OBAD = optimal biologically active dose

* Includes $455.3M in cash, cash equivalents and short-term investments as of 9/30/24 and upfront payment of $330M from strategic collaboration with Kyowa Kirin

KURA ONCOLOGY

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER

November 20, 2024